Ezeamuzie, C I <br/><br/>
Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.  [electronic resource] 

 -  European journal of pharmacology  Apr 2001 
 - 11-8 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0014-2999 
<br/><br/><label>Standard No.: </label>10.1016/s0014-2999(01)00821-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>3',5'-Cyclic-AMP Phosphodiesterases--antagonists & inhibitors<br/>Adenylyl Cyclases--metabolism<br/>Adult<br/>Albuterol--pharmacology<br/>Benzamides--pharmacology<br/>Cell Degranulation--drug effects<br/>Colforsin--pharmacology<br/>Cyclic AMP--metabolism<br/>Cyclic Nucleotide Phosphodiesterases, Type 4<br/>Cyclohexanecarboxylic Acids--pharmacology<br/>Dinoprostone--pharmacology<br/>Dose-Response Relationship, Drug<br/>Enzyme Activation--drug effects<br/>Eosinophil Peroxidase<br/>Eosinophils--drug effects<br/>Histamine--pharmacology<br/>Humans<br/>Nitriles<br/>Peroxidases--drug effects<br/>Phosphodiesterase Inhibitors--pharmacology<br/>Pyridines--pharmacology<br/>Rolipram--pharmacology<br/>Superoxides--metabolism<br/>Theophylline--pharmacology